1. Kor /
  2. Eng

Login Join

  1. Kor /
  2. Eng

Login Join

우수성과SAIHST 구성원의 언론보도내용 및 수상내역, 각 연구분야의 우수 학술지에 게재된 논문 등 우수한 성과들을 소개합니다.

[조주희 교수, 강단비 선임연구원/ 우수논문] JAMA Oncology. 2018 Jun 7
No 1
작성자 관리자
등록일 2018/06/11

공동 교신저자


조주희

(SAIHST 임상연구설계평가학과)

 

 

공동 1저자


강단비

(SAIHST 선임연구원)

 

Impact Factor(‘16): 16.559

 

공단의 표본코호트를 활용하여 암 치료를 받은 환자와 암을 경험하지 않는 대조군의 당뇨병 발생을 장기간(평균 7년) 비교 하여 암을 경험하지 않은 사람에 비해, 암환자에서 당뇨병 발생이 35%나 증가함을 밝힌 연구

 

2018 Jun 7. doi: 10.1001/jamaoncol.2018.1684. [Epub ahead of print]

https://www.ncbi.nlm.nih.gov/pubmed/29879271

 

Incidence of Diabetes After Cancer Development: A Korean National Cohort Study.
Hwangbo Y, Kang D, Kang M, Kim S, Lee EK, Kim YA, Chang YJ, Choi KS, Jung SY, Woo SM, Ahn JS, Sim SH, Hong YS, Pastor-Barriuso R, Guallar E, Lee ES, Kong SY, Cho J.

 

Abstract

 

Importance:

Diabetes is an established risk factor for developing cancer. A limited body of evidence also suggests that cancer can increase the risk of developing new cases of diabetes, but the evidence is inconclusive.

 

Objective:

To evaluate whether the development of cancer is associated with increasing risk of subsequent diabetes.

Design, Setting, and Participants:

This cohort study included a nationally representative sample of the Korean general population observed for up to 10 years (January 1, 2003, to December 31, 2013). A total of 524 089 men and women 20 to 70 years of age without diabetes and with no history of cancer at baseline were included.

 

Exposures:

Incident cancer (time-varying exposure).

Main Outcomes and Measures:

Incident type 2 diabetes using insurance claim codes.

 

Results:

During 3 492 935.6 person-years of follow-up (median follow-up, 7.0 years) in 494 189 individuals (50.0% female; mean [SD] age, 41.8 [12.5] years), 15 130 participants developed cancer and 26 610 participants developed diabetes. After adjustment for age, sex, precancer diabetes risk factors, metabolic factors, and comorbidities, the hazard ratio (HR) for diabetes associated with cancer development was 1.35 (95% CI, 1.26-1.45; P < .001). The excess risk for diabetes was highest in the first 2 years after cancer diagnosis, but it remained elevated throughout follow-up. By cancer type, development of pancreatic (HR, 5.15; 95% CI, 3.32-7.99), kidney (HR, 2.06; 95% CI, 1.34-3.16), liver (HR, 1.95; 95% CI, 1.50-2.54), gallbladder (HR, 1.79; 95% CI, 1.08-2.98), lung (HR, 1.74; 95% CI, 1.34-2.24), blood (HR, 1.61; 95% CI, 1.07-2.43), breast (HR, 1.60; 95% CI, 1.27-2.01), stomach (HR, 1.35; 95% CI, 1.16-1.58), and thyroid cancer (HR, 1.33; 95% CI, 1.12-1.59) was associated with a significantly increased risk of diabetes.

 

Conclusions and Relevance:

In this large Korean cohort, cancer development increased the risk of subsequent diabetes. These data provide evidence that cancer is associated with an increased risk of diabetes in cancer survivors independent of traditional diabetes risk factors. Physicians should remember that patients with cancer develop other clinical problems, such as diabetes, with higher frequency than individuals without cancer, and should consider routine diabetes screening in these patients.

 

 

이전글 다음글

목록보기